Cleveland Clinic launched a monthly irAE tumor board in September 2017. The goal was to obtain specialist opinions about the side effects experienced by immunotherapy patients and to review the latest literature from the rapidly evolving field.
The original irAE tumor board consisted of a handful of oncologists and rheumatologists with specific research interest in immune-related toxicities. Since then, the irAE tumor board has grown to include specialists in gastroenterology, endocrinology, cardiology, infectious disease, urology, pulmonology, and hepatology. Additional specialists sit in on meetings if their specific expertise is required. Approximately 15 to 20 people attend each meeting.
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
